Table 1.
Patient characteristics of study population by concomitant hydrochlorothiazide exposure
| HCTZ, N (%) | No HCTZ, N (%) | |
|---|---|---|
| Total | 581 | 1555 |
| Age at diagnosis (mean (SD)) | 71.5 (4.5) | 71.2 (4.4) |
| Age category | ||
| 66-69 years | 236 (40.2) | 681 (43.8) |
| 70-74 years | 211 (35.7) | 539 (34.7) |
| 75-79 years | 97 (17.3) | 249 (16.0) |
| 80+ years | 37 (6.4) | 86 (5.5) |
| Race | ||
| White | 455 (78.3) | 1308 (84.1) |
| Black | 87 (15.0) | 128 (8.2) |
| Other | 39 (6.7) | 119 (7.7) |
| Stage at diagnosis | ||
| I | 133 (22.9) | 359 (23.1) |
| II | 328 (56.5) | 826 (53.1) |
| III | 120 (20.7) | 370 (23.8) |
| Charlson Comorbidity Score | ||
| 0 | 333 (57.3) | 970 (62.4) |
| 1 | 164 (28.2) | 386 (24.8) |
| 2+ | 84 (14.5) | 199 (12.8) |
| Regimen* | ||
| TC | 295 (50.8) | 824 (53.0) |
| AC | 54 (9.3) | 165 (10.6) |
| CMF | 48 (8.3) | 111 (7.1) |
| DD-AC | 148 (25.5) | 365 (23.5) |
| Other | 36 (6.2) | 90 (5.8) |
| Colony stimulating factor (CSF) | ||
| No | 193 (33.2) | 510 (32.8) |
| Yes | 388 (66.8) | 1045 (67.2) |
*
Regimens include TC (docetaxel + cyclophosphamide or paclitaxel + cyclophosphamide or paclitaxel + docetaxel + cyclophosphamide), AC (doxorubicin + cyclophosphamide), CMF (cyclophosphamide (oral) + methotrexate + fluorouracil), dose-dense AC (doxorubicin + cyclophosphamide + colony stimulating factor), and Other which includes EC (epirubicin + cyclophosphamide), TAC (docetaxel + doxorubicin + cyclophosphamide), and CEF (cyclophosphamide + epirubicin + fluorouracil).